摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S,3S,4S,5S,6R)-2-(4-aminobutoxy)-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol | 1231608-92-6

中文名称
——
中文别名
——
英文名称
(2S,3S,4S,5S,6R)-2-(4-aminobutoxy)-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol
英文别名
(2S,3S,4S,5S,6R)-2-(4-aminobutoxy)-6-(hydroxymethyl)oxane-3,4,5-triol
(2S,3S,4S,5S,6R)-2-(4-aminobutoxy)-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol化学式
CAS
1231608-92-6
化学式
C10H21NO6
mdl
——
分子量
251.28
InChiKey
WYKYJLAXVJZRIC-ZJDVBMNYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -2.4
  • 重原子数:
    17
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    125
  • 氢给体数:
    5
  • 氢受体数:
    7

反应信息

  • 作为反应物:
    描述:
    (2S,3S,4S,5S,6R)-2-(4-aminobutoxy)-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol 、 (2E)-2-[(2E,4E)-5-[3,3-dimethyl-5-sulfonato-1-(3-sulfonatopropyl)indol-1-ium-2-yl]penta-2,4-dienylidene]-3-[6-(2,5-dioxopyrrolidin-1-yl)oxy-6-oxohexyl]-3-methyl-1-(3-sulfonatopropyl)indoline-5-sulfonate tripotassium 在 三乙胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 以34%的产率得到
    参考文献:
    名称:
    [EN] MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS
    [FR] DÉRIVÉS DE MANNOSE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
    摘要:
    本发明涉及用于治疗或预防细菌感染的化合物。这些化合物具有化学式(I)。该发明还提供含有这些化合物的药学上可接受的组合物,以及使用这些组合物治疗细菌感染的方法。最后,该发明提供了制备本发明化合物的方法。
    公开号:
    WO2014100158A1
  • 作为产物:
    描述:
    [(2S,3S,4S,5R,6R)-4,5-diacetoxy-6-(acetoxymethyl)-2-[4-((9H-fluoren-9-ylmethoxy)carbonylamino)butoxy]tetrahydropyran-3-yl] acetate 在 甲醇sodium methylate 作用下, 以88%的产率得到(2S,3S,4S,5S,6R)-2-(4-aminobutoxy)-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol
    参考文献:
    名称:
    Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists
    摘要:
    FimH-mediated cellular adhesion to mannosylated proteins is critical in the ability of uropathogenic E. coli (UPEC) to colonize and invade the bladder epithelium during urinary tract infection. We describe the discovery and optimization of potent small-molecule FimH bacterial adhesion antagonists based on alpha-D-mannose 1-position anomeric glycosides using X-ray structure-guided drug design. Optimized biarylmannosides display low nanomolar binding affinity for FimH in a fluorescence polarization assay and submicromolar cellular activity in a hemagglutination (HA) functional cell assay of bacterial adhesion. X-ray crystallography demonstrates that the biphenyl moiety makes several key interactions with the outer surface of FimH including pi-pi interactions with Tyr-48 and an H-bonding electrostatic interaction with the Arg-98/Glu-50 salt bridge. Dimeric analogues linked through the biaryl ring show an impressive 8-fold increase in potency relative to monomeric matched pairs and represent the most potent FimH antagonists identified to date. The FimH antagonists described herein hold great potential for development as novel therapeutics for the effective treatment of urinary tract infections.
    DOI:
    10.1021/jm100438s
点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
    申请人:UNIV WASHINGTON
    公开号:WO2011050323A1
    公开(公告)日:2011-04-28
    The present invention encompasses compounds and methods for treating urinary tract infections.
    本发明包括用于治疗尿路感染的化合物和方法。
  • [EN] GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES<br/>[FR] INSULINE SENSIBLE AU GLUCOSE COMPRENANT UN GROUPE DE SUCRE TRIVALENT POUR LE TRAITEMENT DU DIABÈTE
    申请人:MERCK SHARP & DOHME
    公开号:WO2018175272A1
    公开(公告)日:2018-09-27
    An insulin conjugate comprising or consisting of a tri-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.
    描述了一种含有三价糖团的胰岛素共轭物。在特定方面,该胰岛素共轭物显示出对系统中的糖类浓度(如葡萄糖或α-甲基甘露糖)具有响应性的药代动力学(PK)和/或药效动力学(PD)特性,即使在向需要该胰岛素共轭物的受试者施用时,不需要外源多价糖类结合分子(如Con A)的存在。
  • COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS
    申请人:Janetka James W.
    公开号:US20120309701A1
    公开(公告)日:2012-12-06
    The present invention encompasses compounds and methods for treating urinary tract infections.
    本发明涵盖了治疗尿路感染的化合物和方法。
  • MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS
    申请人:VERTEX PHARMACEUTICALS INCORPORATED
    公开号:US20130261077A1
    公开(公告)日:2013-10-03
    The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.
    本发明涉及用于治疗或预防细菌感染的化合物。这些化合物的化学式为I:本发明还提供包含这些化合物的药学上可接受的组合物,并提供使用这些组合物治疗细菌感染的方法。最后,本发明提供了制备本发明化合物的方法。
  • Mannose Derivatives for Treating Bacterial Infections
    申请人:Vertex Pharmaceuticals Incorporated
    公开号:US20160235775A1
    公开(公告)日:2016-08-18
    The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.
    本发明涉及用于治疗或预防细菌感染的化合物。这些化合物的化学式为I:本发明还提供了含有这些化合物的药学上可接受的组合物以及使用这些组合物治疗细菌感染的方法。最后,本发明还提供了制备本发明化合物的方法。
查看更多